摘要
冠状动脉粥样硬化性心脏病(冠心病)在全球范围内造成的健康负担显著。其中,低密度脂蛋白胆固醇(LDL-C)水平控制是治疗的关键。近年来,由于前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂具有独特的作用机制和显著降低LDL-C的能力,已成为冠心病治疗的首选药物。然而,患者对PCSK9抑制剂的治疗依从性存在显著差异,这直接影响药物的临床效果。本研究通过广泛的数据库查询和文献回顾,旨在综合分析影响冠心病患者对PCSK9抑制剂治疗依从性的多种因素,如经济负担、患者教育水平、副作用感知、治疗期望、药品覆盖等,旨在为临床提供一个全面的依从性改善框架,以期提高冠心病患者的治疗效果,减轻其总体负担。
Coronary atherosclerotic heart disease(CHD)causes a significant global health burden,among which the control of low-density lipoprotein cholesterol(LDL-C)level is a key treatment strategy.In recent years,inhibitors of pre protein converting enzyme Bacillus subtilis lysozyme 9(PCSK9)have become a first-line choice for the treatment of coronary heart disease due to their unique mechanism of action and ability to significantly reduce LDL-C.However,there are significant differences in patient adherence to PCSK9 inhibitors,which directly affects the clinical efficacy of the drugs.This study aims to comprehensively analyze various factors that affect the compliance of coronary heart disease patients with PCSK9 inhibitors,such as economic burden、patient education level、perception of side effects、treatment expectations、drug coverage,etc.,through extensive database searches and literature reviews.It provides a comprehensive compliance improvement framework for clinical healthcare workers,aiming to improve treatment effectiveness and reduce the overall burden on coronary heart disease patients.
作者
郑晓芳
Zheng Xiaofang(Department of Cardiovascular Medicine The Eighth Affiliated Hospital of Sun Yat-Sen University(Shenzhen Futian),Shenzhen Guangdong 518033,China)
出处
《生命科学仪器》
2024年第5期78-80,共3页
Life Science Instruments
基金
2022年深圳市福田区卫生健康科研项目,项目编号:FTWS2022054
关键词
前蛋白转化酶枯草溶菌素9抑制剂
冠心病
低密度脂蛋白胆固醇
治疗依从性
Proprotein convertase subtilisin 9 inhibitor
Coronary heart disease
Low-density lipoprotein cholesterol
Treatment compliance
